QuantRx Biomedical Corporation announced continued progress and exciting development across its business lines. As previously reported, the Company's continued efforts to secure a domestic manufacturing source for it miniform pads is critical to the ongoing development and commercialization of its laboratory diagnostics and genomic testing product offerings that are based on its patented PadKit technology. PadKit uses the biologic material collected by the Pads as the basis for diagnostic testing and analysis.

In its quest to become the innovator in maternal and fetal genomic diagnostics, the Company has demonstrated the presence of both maternal and fetal DNA in PadKit samples collected from pregnant women in its early trials. While the optimization of this technology is still in the development stage, with studies progressing towardsthe reliable and robust purification of the entire fetal genome collected via the PadKit, the potential ramifications for both maternal and fetal predictive medicine could prove transformational. The PadKit offers a safe, non-invasive and easily repeatable method for acquiring genetic data from women of all ages, pregnant or not.

Given today's dramatic reduction in the cost of a full genomic analysis, the capabilities afforded by its unique and proprietary technology ideally positions the Company to capitalize on the rapidly expanding field of genomic research and the numerous commercial applications thereof. The recently proposed initiative by the Obama administration to acquire DNA samples from one million individuals is further evidence of the growing trend and represents a perfect application for the Company's PadKit.